Insys Therapeutics (NASDAQ: INSY) reported Q3 EPS of $0.00, $0.02 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $55.2 million versus the consensus estimate of $55.97 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.